With our newest content you can stay one step ahead of your competitors as we explore our analysis in various different ways, allowing you to process it as you need.
Contact Us If you want to know more about what analysis we have on biosimilars, or would like to talk to someone about this report, simple request a call back to learn more...
Biosimilars offer significant opportunities, but only players with well-positioned offerings will see success in this challenging market.
Our newest report provides insight for newcomers to the topic through to those experienced in biosimilars. Trends are presented showing how things have changed over the last five years and what that means going forwards.
A key focus is on the number of biosimilar versions in development, since this will ultimately impact the market share and sales achieved by each.
Not only will you be able to make more educated decisions about how and why you should be investing in this market, you’ll excel at it.
Approval of the US biosimilar approval pathway has coincided with increased Big Pharma activity and a surge in new Phase III clinical trials. 2014 was a standout year for innovator biologic approvals, with more than 100 now authorized in the US.
Make sure you know what is happening across the global biosimilar market by downloading our webinar with Giles Somers. He talks you through the landscape for biosimilars and how it has evolved over the past five years and what the outlook is going forward.
Key questions answered within this webinar:
Significant progress has been made with biosimilars over the last five years. We’ve produced an infographic that will give you a quick insight into how the landscape has evolved and what the outlook will be going forwards.
Informa Life Sciences’ Annual Biosimilars 2015 conference will provide you with the latest regulatory, CMC, market access, clinical and commercialisation updates to optimise biosimilar development.
Join us in the Maritim proArte Hotel Berlin, Germany on 18-20 May 2015, to gain critical feedback from Paul-Ehrlich-Institut, Finnish Medicines Agency, Austrian Medicines & Medical Devices Agency (AGES), and Norwegian Medicines Agency on their expectations for submissions, substitution and designing clinical trials.
Request your FREE demo here We're more than just biosimilars... At Datamonitor Healthcare we provide details and accurate analysis on a range of different disease indications, company types and hot topics. If you'd like to know about how we can add value to your business and put you one step ahead of your competitors just request your free demo below...
You now have full access to all articles on our site for the next 28 days.